Ipsen is a global specialty driven pharmaceutical company with total sales exceeding . billion in . Ipsen s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology, endocrinology and uro oncology. Moreover, the Group has an active policy of partnerships. R amp D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In , R amp D expenditure totaled close to million, representing more than of Group sales. The Group has total worldwide staff of close to , employees.
Quote | Ipsen Sa Ord (OTCMKTS:IPSEF)
Last: | $131.1968 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $131.1968 |
High: | $0 |
Low: | $0 |
Volume: | 494 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Ipsen Sa Ord (OTCMKTS:IPSEF)
2024-07-14 06:44:00 ET Summary Foreseen Biotechnology out-licensed global rights for an ADC candidate to France’s Ipsen in a deal potentially worth over $1 billion. Biokin Pharma filed to stage an IPO on the Hong Kong Exchange that could raise $500 million. Keymed Biosc...
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel tumor associated antigen, highly expressed across a range of solid tumors, identified throug...
Message Board Posts | Ipsen Sa Ord (OTCMKTS:IPSEF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Ipsen Sa Ord Company Name:
IPSEF Stock Symbol:
OTCMKTS Market:
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel tumor associated antigen, highly expressed across a range of solid tumors, identified throug...
Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx ® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreemen...
Iqirvo ® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholan...